What Comes First? FDA Excessive Claims Finding Or Facility Inspection?
This article was originally published in The Tan Sheet
Executive Summary
Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.
You may also be interested in...
Soap Maker Warned As FDA's Cosmetics Enforcement Activity Picks Up
FDA has issued three warning letters to cosmetic product marketers over the past month. The agency cites Soapwalla for violative claims on bar soaps, while Star Health & Beauty's purported cosmetics and dietary supplements are not only unapproved drugs, but also adulterated in some cases due to GMP violations.
FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
FDA cites Reviva for unapproved drug claims on eight of its products marketed as cosmetics. Included among targeted claims are familiar statements about collagen production, inflammation reduction and other benefits the agency views as structure/function effects. A number of the claims onceivably could be allowed under the revised "cosmetic" definition proposed by the Cosmetic Modernization Amendments of 2015.
FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims
In a warning letter published on FDA's website May 2, the agency identifies two Ageless Derma products as unapproved new drugs due to label and website claims touting body structure/function effects. The laundry list of offending claims offers a resource for companies to use in their own claims-compliance efforts.